Brigatinib approved for use in EU as monotherapy for first line use in ALK+ve non-small-cell lung cancer

The approval is based on results from the Phase III ALTA-1L trial, which showed that the drug demonstrated superiority in this treatment setting compared to crizotinib with significant anti-tumor activity observed in patients with baseline brain metastases.